Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Phase 4

Completed

• Conditions: Type-2 Diabetes Mellitus
• Interventions: Drug: LAF237 (vildagliptin); Drug: Metformin

• Registration Number: NCT01766778
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-01-09
• Study First Submitted QC: 2013-01-09
• Study First Posted: 2013-01-11
• Study Start: 2013-05-13
• Primary Completion: 2015-10-22
• Study Completion: 2015-10-22
• Results First Submitted: 2017-02-23
• Results First Submitted QC: 2017-02-23
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-07
• Results First Posted: 2017-04-10
• Last Update Posted: 2017-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 117

Inclusion Criteria

1. Male or Female in age ≥18 at Visit 1
2. Type 2 diabetes mellitus (T2DM) patients on their maximum tolerated dose of Metformin for more than 3 months
3. HbA1c (glycosylated hemoglobin) at Visit 1 greater than 7.0%
4. With nearest documented record of HbA1c before Visit 1 greater than 7.0% after patient reached his/her maximum tolerated dose of Metformin

Key

Read More

Exclusion Criteria

1. Patients with hepatic impairment, including patients with a pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 X the upper limit of normal at Visit 1
2. Patients with moderate or severe renal impairment or end-stage-renal-disease (ESRD) on haemodialysis at the time of enrolment
3. Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption
4. Pregnant women or breastfeeding women at the time of enrolment
5. Use of insulin or other oral anti-diabetic drug (OAD) apart from Metformin in the past for T2DM treatment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LAF237 (vildagliptin) 50mg once daily (QD)	LAF237 (vildagliptin)	Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
LAF237 (vildagliptin) 50mg twice daily (BID)	LAF237 (vildagliptin)	Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
LAF237 (vildagliptin) 50mg once daily (QD)	Metformin	Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
LAF237 (vildagliptin) 50mg twice daily (BID)	Metformin	Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin

Primary Outcome Measures

Name	Time	Method
Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12	Baseline, Month 12 (weeK 52)	HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c

Secondary Outcome Measures

Name	Time	Method
Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)	Baseline, Month 3, 6, 9 and 12	HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model includes terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by age, pre-existing hypertension and microvascular and macrovascular complications for diabetes mellitus. The variables selected for baseline adjustment were based on the lowest AIC.
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)	Baseline, Month 3, 6, 9 and 12	Blood samples were collected to analyze fasting plasma glucose. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model included terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by pre-existing hypertension. The variable selected for baseline adjustment was based on the lowest AIC.
Percentage of Patients Achieving Good Glycemic Control	Month 3, 6, 9, 12	Blood samples were collected to analyze HbA1c. Good glycemic control is defined as patient achieving Hb1Ac \< 7.0%. Percentage of patients who achieved HbA1c less than 7.0% at month 3, 6, 9 and 12 were reported for this endpoint.
Percentage of Overall Drug Compliance in 12 Months	Month 12	The overall drug compliance (%) = (Observed Consumption / Expected Consumption) x 100% Where (Observed Consumption / Expected Consumption) = \[1- (Number of missing tablets from all visits/(sum of Allocated Daily Dosage (in tablets) from all visits × No. of Days between the Date Dispensed and the Date Returned))\]
Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability	Month 12	This analysis reported percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death was reported.

Trial Locations

Locations (1)

Novartis Investigative Site; 🇭🇰 Tuen Mun, Hong Kong